Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 57

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 57
---
 own names, so that they will be direct holders. We have described the rights of holders and street name investors above. Unless we provide otherwise in the applicable prospectus supplement, a global security will terminate when the following special situations occur:

| • |     | if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for 
 that global security and we do not appoint another institution to act as depositary within 90 days;             |

| • |     | if we notify any applicable trustee that we wish to terminate that global security; or |

| • |     | if an event of default has occurred with regard to securities represented by that global security and has not 
 been cured or waived.                                                                                         |

The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. 25

SELLING STOCKHOLDERS The shares of Common Stock being offered by the selling stockholders consist of 9,321,545 shares of our Common Stock comprising up to (i) 4,570,629 shares of our Common Stock and (ii) 4,750,916 shares of our Common Stock issuable upon the exercise of warrants. The shares of Common Stock have been issued or are issuable in connection (i) the Securities Purchase Agreement dated as of June 2, 2025 (the “Securities Purchase Agreement”), (ii) a selling stockholder’s exercise of warrants to purchase 45,765 shares of Common Stock, and (iii) placement agent warrants issued in connection with the Private Placement (see definition below). We are registering the shares of Common Stock in order to permit the selling stockholders to offer the shares for resale from time to time in accordance with the terms of the Securities Purchase Agreement. On June 2, 2025, we and the selling stockholders (the “Purchasers”) entered into the Securities Purchase Agreement pursuant to which we agreed to issue to the Purchasers, in a private placement (the “Private Placement”), an aggregate of 4,759,309 shares of Common Stock together with warrants to purchase an equal number of shares of Common Stock at an exercise price of $3.3125 (the “Private Placement Warrants”), for an aggregate offering amount of approximately $